Triumvira Immunologics to Present New Data on its TAC T Cell Autologous and Allogeneic Products and the Ongoing Phase I/II Solid Tumor Trial at the 2023 AACR Annual Meeting
AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., March 15, 2023 /PRNewswire/ -- Triumvira Immunologics, Inc., a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the Company will be presenting preclinical and clinical data on its lead asset TAC01-HER2 for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, April 14-19. The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 (NCT04727151) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.
"We are pleased to present additional validation of our lead clinical program TAC01-HER2, currently in Phase I/II trials, supporting the efficiency of our proprietary Cocoon® platform to manufacture potent autologous TAC01-HER2 cells using leukocytes from cancer patients," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics. "Interim results will also be presented from our ongoing Phase I/II trial investigating the safety and efficacy of autologous TAC01-HER2 in HER2+ refractory solid tumors demonstrating a favorable safety profile and promising clinical activity as evident by reduction of measurable disease and prevention of fast cancer progression in the majority of patients enrolled in the Phase I trial. Further, we will present new preclinical data from our allogeneic T cell-based products in development demonstrating their potential to avoid graft versus host disease."
Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors
Title: Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform are highly functional in models of solid tumors
Title: Preclinical characterization of allogeneic Vγ9Vδ2 HER2-TAC T cells for the treatment of HER2-positive solid tumors
Abstracts are currently available on the AACR website. A copy of the presentations will also be available after the closure of the meeting on April 19, under the Presentations & Publications tab of the News & Resources section of the Company's website.
About Triumvira Immunologics
Triumvira Immunologics, Inc. ("Triumvira") is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario, and San Francisco, California.
View original content to download multimedia:https://www.prnewswire.com/news-releases/triumvira-immunologics-to-present-new-data-on-its-tac-t-cell-autologous-and-allogeneic-products-and-the-ongoing-phase-iii-solid-tumor-trial-at-the-2023-aacr-annual-meeting-301772509.html
SOURCE Triumvira Immunologics